United Kingdom & Eli Lilly and Company

United Kingdom: NHS prescribes Tirzepatide; MHRA monitors safety reports.

Eli Lilly and Company: Manufacturer of Tirzepatide; reported strong sales growth and benefits from positive study results.

United Kingdom: The 10-year UK gilt yield rose, reflecting movements in European government bond yields.

Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.

United Kingdom: Heart attacks and strokes are leading causes of death in the United Kingdom>>>, highlighting the global relevance and potential impact of VERVE-102.

Eli Lilly and Company: As the parent company of Verve PCSK9-inhibitor gene therapy>>>, Eli Lilly and Company>>> is a key developer of VERVE-102, a gene-editing therapy that has shown promising results in lowering cholesterol. This breakthrough could significantly impact its future market position in cardiovascular medicine.

United Kingdom: FTSE 100 slightly higher; energy stocks support.

Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.

United Kingdom: The United Kingdom is mentioned for a past study on GLP-1 drugs and sickness days. Not directly involved in this study.

Eli Lilly and Company: Eli Lilly manufactures Mounjaro and Zepbound, GLP-1 drugs included in the study. The findings could enhance the perceived economic value of its products.

United Kingdom: The UK also approved Wegovy for MASH, contributing to the global expansion of the drug's indications.

Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in India's obesity-drug market with Mounjaro; the approval may intensify competition.

Eli Lilly and Company: Eli Lilly and Company collaborated on a new study that found a 71% higher risk of cardiovascular events or death in people with obstructive sleep apnea, especially those with obesity. This research could influence the development of new treatments and diagnostics, potentially benefiting Eli Lilly and Company's market position in related therapeutic areas.

Eli Lilly and Company: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.